Juvenile RA/Pediatric Rheumatology

Sangeeta Sule, M.D.

Abstract 659: Long-Term Efficacy and Safety of Adalimumab in Children with Juvenile Rheumatoid Arthritis (JRA): 48 Week Results

Abstract 718: Preliminary Evidence for Bioactivity of IL-1 Trap (Rilonacept), A Long Acting IL-1 Inhibitor, in Systemic Juvenile Idiopathic Arthritis (SJIA)

Abstract 719: Assessment of Open Label Co-Stimulation Blockade with Abatacept in Children and Adolescents with Active Juvenile Idiopathic Arthritis (JIA)

Abstract 722: Rapid Improvement of Signs and Symptoms Associated with Systemic Juvenile Idiopathic Arthritis (sJIA) by Interleukin-6 (IL-6) Blockade - Results from a Tocilizumab sJIA Phase III Clinical Trial

Abstract 723: A Randomized, Multi-Center, Blinded, Placebo-Controlled Study With an Open-label Run-in Period to Evaluate Anakinra in Polyarticular-Course Juvenile Rheumatoid Arthritis

Abstract Number 1700 - Mycophenolate Mofetil (MMF) in Juvenile Dermatomyositis

• Rheumatoid Arthritis
• Treatment Strategies
• TNF Antagonists
• B-Cell Depletion
• Other Agents
• OA Clinical Aspects
• Juvenile RA / Pediatric Rheumatology
• Systemic Lupus Erythematosus
• Vasculitis
• Scleroderma
• Fibromyalgia
• Spondyloarthropathies
• Myositis
• Pregnancy in AutoImmune Disease
• Non-Pharmacologic Management
• Basic Science
• Epidemiology
• Psychosocial